Highlights from the 12th World Conference on Lung Cancer - CME
Chandra Belani, MD, Penn State Cancer Center, Hershey, PA; David Spigel, MD, The Sarah Cannon Research Institute, Nashville, TN; David Jackman, MD, Dana-Farber Cancer Institute, Boston, MD.

12th World Conference on Lung Cancer: Updates in the Management of Early Stage Non-Small Cell Lung Cancer (NSCLC) - CME
Chandra Belani, MD, Penn State Cancer Center, Hershey, PA

12th World Conference on Lung Cancer: Advances in the Management of Advanced NSCLC: Are We Making Progress? - CME
David Spigel, MD, The Sarah Cannon Research Institute, Nashville, TN

12th World Conference on Lung Cancer: Malignant Pleural Mesothelioma Updates - CME
David Jackman, MD, Dana-Farber Cancer Institute, Boston, MA

12th World Conference on Lung Cancer: Advances in the Management of Small-Cell Lung Cancer (SCLC) - CME
David Spigel, MD, The Sarah Cannon Research Institute, Nashville, TN

Iressa® Superior to Platinol® and Taxotere® for Treatment of NSCLC with EGFR Mutations (2/5/2010)
Researchers from Japan have reported that Iressa® (gefitinib) alone improves progression-free survival (PFS) of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) with epithelial growth factor receptor (EGFR) mutations compared with patients receiving Platinol® (cisplatin) plus Taxotere® (docetaxel). The details of this study were published in the February 2010 issue of Lancet Oncology.

Figitumumab Active in Lung Cancer, Adrenocortical Carcinoma, Ovarian Cancer, and Ewing’s Sarcoma (1/11/2010)
Recent Phase I and II studies have suggested that figitumumab, a monoclonal antibody that targets insulin-like growth factor-1 receptor, is active for the treatment of several cancers.

Hospitalization for Pneumonia Leads to Diagnosis of Lung Cancer in 9% (12/30/2009)
Researchers from several U.S. medical centers have reported that 9% of patients hospitalized with pneumonia were diagnosed with pulmonary malignancy, but the median time from hospitalization to diagnosis is 297 days. The details of this study were published in the January 2010 issue of the American Journal of Medicine.

Anti-estrogens May Reduce Risk of Lung Cancer Death (12/15/2009)
Researchers from Switzerland have reported that anti-estrogens (such as tamoxifen [Nolvadex®]) used as treatment for breast cancer may also reduce the risk of death from lung cancer. The details of this study were presented at the 2009 San Antonio Breast Cancer Symposium.

Volume and Doubling Time Used to Determine Significance of Nodules in CT Screening for Lung Cancer (12/4/2009)
Researchers involved in the Dutch–Belgian randomized lung cancer screening trial (Nederlands-Leuvens Longkanker Screenings Onderzoek [NELSON]) have reported that a strategy of using the volume and volume-doubling time of a noncalcified nodule as the main criteria for further work-up may improve the efficiency of CT screening for lung cancer. The details of this study appeared in the December 3, 2009 issue of the New England Journal of Medicine.